At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History
In Brief
A Phase 2 clinical trial evaluating bevacizumab, carboplatin, and 2 other interventions for Lung Cancer. Completed, enrolled 38 participants across 4 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving carboplatin and pemetrexed disodium together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin and pemetrexed disodium together with bevacizumab works in treating patients with stage III or stage IV non-small cell lung cancer who are light or never smokers.
Study Details
Timeline
Interventions
15 mg/kg once per 21 day cycle (up to 4 cycles).
Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
150mg, daily for 21 day cycle (up to 4 cycles)
500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)